Your Cart


1H2023 Half-Year Results

1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan

Read More

Imagion Announces New CEO

MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, is pleased to announce it has appointed Isaac

Read More

2023 AGM Resolution Overview

Video Transcript: Robert Proulx, Imagion Biosystems’ President & CEO: [00:00:00] On April 24th, we sent out the notice of meeting for our annual general meeting

Read More

Imagion Funding Update

Highlights:  Shareholder entitlement offer seeking to raise up to $2.4 million Funding facility of up to $15 million secured with Mercer Street Global Opportunity Fund,

Read More

Imagion Secures Growth Funding

Highlights:  Imagion secures a funding facility of up to $15 million to support next phase of clinical and oncology pipeline development Funding Facility includes: $1.5 million

Read More

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.